You have 7 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

neuroblastoma dinutuksymab beta chemoimmunotherapy

Showing 1 - 25 of 3,417
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

High-Risk Neuroblastoma Trial in Krakow (Chemoimmunotherapy (Dinutuximab beta in combination with chemo))

Recruiting
  • High-Risk Neuroblastoma
  • Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)
  • Krakow, Malopolska, Poland
    University Children Hospital
Mar 8, 2022

Neuroblastoma, Ganglioneuroblastoma Trial in Moscow (monoclonal antibodies GD2)

Recruiting
  • Neuroblastoma
  • Ganglioneuroblastoma
  • monoclonal antibodies GD2
  • Moscow, Russian Federation
    Research Institute of Pediatric Hematology, Oncology and Immunol
Oct 4, 2023

Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma Trial in Atlanta (Ex Vivo Expanded Allogeneic ?d T Cells in

Not yet recruiting
  • Neuroblastoma
  • +2 more
  • Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate
  • Atlanta, Georgia
    Children's Healthcare of Atlanta
Oct 6, 2022

Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma Trial in United States (OPT-821 (QS-21), oral ß-glucan)

Recruiting
  • Neuroblastoma
  • +2 more
  • OPT-821 (QS-21)
  • oral β-glucan
  • Basking Ridge, New Jersey
  • +6 more
Sep 21, 2023

High-risk Neuroblastoma Trial in China (Dinutuximab Beta, 13 cis retinoic acid)

Active, not recruiting
  • High-risk Neuroblastoma
  • Dinutuximab Beta
  • 13 cis retinoic acid
  • Beijing, Beijing, China
  • +3 more
Dec 7, 2022

Locally Advanced, NSCLC Trial in Shanghai (drug, procedure, radiation)

Recruiting
  • Locally Advanced
  • Non-small Cell Lung Cancer
  • Shanghai, China
    Shanghai Pulmonary Hospital
Mar 14, 2023

Neuroblastoma (NB) Trial in New York (Irinotecan, temozolomide, Hu3F8)

Active, not recruiting
  • Neuroblastoma (NB)
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 19, 2021

Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer

Recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • CT/PET/WSI-based Deep Learning Signature
  • Zunyi, Guizhou, China
  • +2 more
Jun 27, 2023

Neuroblastoma Trial in New York (dietary supplement, drug, biological)

Recruiting
  • Neuroblastoma
  • β-glucan
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Dec 5, 2022

Non Hodgkin Lymphoma Trial in United Kingdom (R-CHOP + acalabrutinib)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • R-CHOP + acalabrutinib
  • Southampton, Hampshire, United Kingdom
  • +6 more
Oct 26, 2022

DLBCL Trial (Acalabrutinib, Rituximab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • (no location specified)
Jul 11, 2023

Triple Negative Breast Cancer, Breast Cancer Trial in United States (Carboplatin, Docetaxel, Doxorubicin)

Recruiting
  • Triple Negative Breast Cancer
  • Breast Cancer
  • Fairway, Kansas
  • +5 more
Jan 26, 2023

Neuroblastoma Trial (Naxitamab)

Not yet recruiting
  • Neuroblastoma
  • (no location specified)
Sep 18, 2023

Neuroblastoma Patients

Not yet recruiting
  • Neuroblastoma
    • San Francisco, California
      Power Life Sciences
    Jun 15, 2023

    Neuroblastoma Trial in New York (beta-glucan, mAb 3F8, immunohistochemistry staining method)

    Completed
    • Neuroblastoma
    • beta-glucan
    • +3 more
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Mar 4, 2022

    ctDNA Testing Plus AI-based Pathology in Resectable LSCC

    Recruiting
    • Lung Squamous Cell Carcinoma
    • WES and ctDNA detection
    • Changsha, Hunan, China
      Department of Thoracic Surgery, Second Xiangya Hospital of Centr
    Mar 18, 2023

    Chronic Lymphocytic Leukemia Trial in Worldwide (Acalabrutinib, Venetoclax, Chemoimmunotherapy)

    Recruiting
    • Chronic Lymphocytic Leukemia
    • Fountain Valley, California
    • +201 more
    Jan 16, 2023

    Leukemia, Lymphoma Trial in Houston (Ofatumumab)

    Active, not recruiting
    • Leukemia
    • Lymphoma
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Dec 9, 2022

    Neuroblastoma Trial in Worldwide (Data-collection)

    Recruiting
    • Neuroblastoma
    • Data-collection
    • Wien,, Vienna, Austria
    • +13 more
    Oct 28, 2022

    Neuroblastoma Trial (GD2 CAR T cells)

    Not yet recruiting
    • Neuroblastoma
    • GD2 CAR T cells
    • (no location specified)
    Aug 5, 2023

    Glioblastoma Trial in Louisville (Pembrolizumab and Temozolomide)

    Recruiting
    • Glioblastoma
    • Pembrolizumab and Temozolomide
    • Louisville, Kentucky
      James Graham Brown Cancer Ctr.
    Jan 18, 2023

    ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • NGS and ctDNA-MRD detection
    • Changsha, Hunan, China
      Department of Thoracic Surgery, Second Xiangya Hospital of Centr
    Apr 18, 2023

    Primary Mediastinal B-cell Lymphoma Trial in Worldwide (observation, 3D-Conformal Radiotherapy (3D-CRT))

    Active, not recruiting
    • Primary Mediastinal B-cell Lymphoma
    • observation
    • 3D-Conformal Radiotherapy (3D-CRT)
    • Louisville, Kentucky
    • +84 more
    Aug 17, 2022

    Head Neck Cancer, Lung Cancer Trial in New Brunswick (Paclitaxel, Pemetrexed, 5Fluorouracil)

    Recruiting
    • Head and Neck Cancer
    • Lung Cancer
    • Elizabeth, New Jersey
    • +10 more
    Oct 13, 2022

    Patients With Previously Diagnosed High-Risk Neuroblastoma

    Active, not recruiting
    • Recurrent Neuroblastoma
    • +5 more
    • Cytology Specimen Collection Procedure
    • +2 more
    • Birmingham, Alabama
    • +97 more
    Oct 28, 2022